Product image of Optruma (Raloxifene Hydrochloride) supplied by GNH India

Optruma

Active Ingredient:
Raloxifene Hydrochloride
Origin:
EU

Optruma (Raloxifene Hydrochloride)

Raloxifene hydrochloride, the active ingredient in Optruma, is a selective estrogen receptor modulator presented as an oral tablet for oral use. It is indicated for the prevention and treatment of osteoporosis in postmenopausal women and for reducing the risk of invasive breast cancer in women at high risk.
GNH India supplies Optruma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Eli Lilly Nederland B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Optruma is a selective estrogen receptor modulator used in bone‑related and hormone‑sensitive conditions.

  • Osteoporosis: helps maintain bone density and lowers the risk of fractures in postmenopausal women.
  • Postmenopausal bone loss: reduces bone resorption, supporting overall skeletal health.
  • High‑risk breast cancer: lowers the incidence of invasive breast cancer in women identified as high risk.

How It Works

  • Raloxifene hydrochloride binds to estrogen receptors, acting as an antagonist in breast and uterine tissue while functioning as an agonist in bone. This selective activity decreases osteoclast‑mediated bone resorption, thereby preserving bone mineral density, and simultaneously blocks estrogen‑driven proliferation in breast cells, contributing to cancer risk reduction.

Side Effects

Common Side Effects

  • Hot flashes: transient warmth and sweating.
  • Leg cramps: muscle tightness, often in calves.
  • Peripheral edema: mild swelling of the lower extremities.
  • Nausea: occasional upset stomach.
  • Headache: mild to moderate intensity.
  • Dizziness: feeling light‑headed.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in deep veins.
  • Pulmonary embolism: blockage of lung arteries.
  • Stroke: cerebrovascular incident.
  • Myocardial infarction: heart attack.
  • Severe allergic reaction: rash, swelling, breathing difficulty.
  • Liver function abnormalities: elevated enzymes.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly.

  • Bone density assessment: confirm osteoporosis diagnosis before treatment.
  • Thromboembolic history: avoid in patients with prior clotting events.
  • Cardiovascular risk: monitor for signs of stroke or myocardial infarction.
  • Pregnancy and lactation: contraindicated; ensure effective contraception.
  • Drug interactions: review concurrent medications for potential interactions.
  • Store at below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Raloxifene may interact with several medicines, requiring careful management.

Major Interactions (Avoid)

  • Estrogen therapy: increases thromboembolic risk.
  • Tamoxifen: antagonistic effect on breast tissue.
  • Warfarin: may enhance anticoagulant effect.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inhibitors (e.g., ketoconazole): raise raloxifene levels.
  • SSRIs: potential impact on bone metabolism.
  • Calcium or vitamin D supplements: may affect absorption.

Frequently Asked Questions

Optruma contains raloxifene hydrochloride and is prescribed to prevent and treat osteoporosis in postmenopausal women and to lower the risk of developing invasive breast cancer in women who are identified as high‑risk.

Raloxifene acts as a selective estrogen receptor modulator: it blocks estrogen receptors in breast and uterine tissue while stimulating them in bone. This dual action reduces bone loss and inhibits estrogen‑driven breast cell proliferation.

The specific dose and dosing schedule of Optruma are determined by the prescribing clinician based on the patient’s medical condition, bone density results, and overall health status. Patients should follow the prescriber’s instructions exactly.

Raloxifene is classified as contraindicated in pregnancy and breastfeeding because its safety has not been established. Women of child‑bearing potential should use effective contraception while taking the medication.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike bisphosphonates, which inhibit bone resorption directly, raloxifene modulates estrogen receptors, offering bone‑preserving benefits while also providing breast‑cancer risk reduction. Its safety profile differs, with a lower incidence of gastrointestinal irritation but a higher concern for thromboembolic events.

Store Optruma tablets at temperatures below 25 °C, in the original packaging, and protect them from moisture and direct sunlight to maintain product stability.

Optruma is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew it.

The most serious risks include venous thromboembolism, pulmonary embolism, stroke, and myocardial infarction. Patients should be educated to seek immediate medical attention if they experience leg pain, swelling, sudden shortness of breath, chest pain, or neurological symptoms.

Optruma should not be used by individuals with a history of deep‑vein thrombosis, pulmonary embolism, stroke, or active liver disease, and it is contraindicated in pregnant or breastfeeding women. Patients with known hypersensitivity to raloxifene should also avoid the medication.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Raloxifene Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT